Spero Therapeutics, Inc.
Spero Therapeutics, Inc. (SPRO) Stock Overview
Key statistics and deep links to earnings, valuation, revenue, dividends, and more.
FMP · SPRO · as of Jun 9, 2026
Key Statistics
Explore Spero Therapeutics, Inc. Data
spro stock data · financialsFinancial Snapshot
Full FinancialsAnalyst Ratings & Price Target
Full ForecastTotal: 13 · Buy rate: 46.2%
Competitors & Peers
spro competitorsSPRO
ABOS
ACTU
CGTX
CRBP
HURAStock Performance
Full HistoryAbout Spero Therapeutics, Inc.
Spero Therapeutics, Inc. is a biopharmaceutical firm in the clinical development stage, primarily focused on discovering, advancing, and commercializing innovative treatments for multi-drug resistant …
what is spero therapeutics, inc. · spro stock overview · spero therapeutics, inc. company profile · who is spero therapeutics, inc. ceo · spro NASDAQ · spero therapeutics, inc. headquarters · spero therapeutics, inc. business segments
About Stock Overview & Key Data
Spero Therapeutics, Inc. (SPRO) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Nov 2, 2017. As of the latest trading session, SPRO stock price is $2.74, with a market capitalization of $158.7M. The stock has returned -0.72% over the past 12 months and +17.60% year-to-date.
According to 13 Wall Street analysts, the consensus rating for Spero Therapeutics, Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, Spero Therapeutics, Inc. reported revenue of $59.6M and net income of $8.6M. For detailed data — including Spero Therapeutics, Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.
Frequently Asked Questions
As of the latest trading session, Spero Therapeutics, Inc. (SPRO) stock price is $2.74. The stock is traded on NASDAQ under the ticker symbol SPRO. The 52-week range is $1.80 – $3.22.